AbbVie seeks FDA approval for Pivekimab Sunirine to treat rare, aggressive blood cancer
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
The platform is being introduced to expand access to treatments for people living with chronic conditions
The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Subscribe To Our Newsletter & Stay Updated